Climb Bio, Inc.

NasdaqGM:CLYM Aktierapport

Börsvärde: US$858.7m

Climb Bio Förvaltning

Förvaltning kriterier kontrolleras 2/4

Vi har för närvarande inte tillräcklig information om VD:n.

Viktig information

Aoife Brennan

Verkställande direktör

US$2.9m

Total ersättning

VD-lön i procent22.91%
Anställning som VD2.3yrs
Ägande av VD0.2%
Ledningens genomsnittliga anställningstid1.1yrs
Styrelsens genomsnittliga mandatperiod1.8yrs

Senaste uppdateringar av ledningen

Recent updates

Analysartikel • Aug 08

Climb Bio (NASDAQ:CLYM) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Climb...
Seeking Alpha • Jul 23

Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility

Summary Climb Bio has surged >160% YTD, driven by anticipation for pivotal Phase 2/1b data in pMN, ITP, and SLE due by year-end 2026. Budoprutug, a CD19-targeting monoclonal antibody, has shown promising early safety and efficacy signals across multiple autoimmune indications, with Fast Track status in pMN. CLYM’s strong cash position ($146.3m, no significant debt) supports operations into 2028, but future Phase 3 trials will likely require dilutive capital raises. Upcoming data readouts are high-stakes; positive results could drive further upside, while underwhelming data may cause the stock to lose up to half its value. Read the full article on Seeking Alpha
Analysartikel • Feb 07

Here's Why We're Watching Climb Bio's (NASDAQ:CLYM) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 23

Eliem Therapeutics: Recent Strategic Pipeline Restructuring

Summary Eliem Therapeutics, founded in 2019, shifted focus to autoimmune diseases with the acquisition of Tenet Medicines and its lead molecule, budoprutug. Budoprutug targets CD19-positive B cells, aiming to treat SLE, ITP, and MN by reducing pathogenic autoantibodies and improving disease symptoms. Early clinical trials for MN showed promising results, with 60% of patients achieving complete remission of proteinuria, supporting further development. Despite a decent market cap and cash reserves, ELYM's early-stage status and single-molecule focus make it a cautious watch rather than an immediate investment. Read the full article on Seeking Alpha
Seeking Alpha • Jun 28

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Summary Results from Eliem Therapeutics, Inc.'s phase 1b study, using TNT119 for the treatment of patients with membranous nephropathy, expected by the end of 2024. It is expected that the global membranous nephropathy treatment market could reach $328.4 million by 2034. Two other large market indications that can be targeted using TNT119 are systemic lupus erythematosus and immune thrombocytopenia. Acquisition of Tenet Medicines and $120 million private placement agreement provide funding for operations into 2027, with cash on hand at $220 million. Read the full article on Seeking Alpha
Analysartikel • Feb 01

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysartikel • Jun 24

We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysartikel • Mar 08

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysartikel • Nov 18

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Aug 15

Eliem Therapeutics GAAP EPS of -$0.56 misses by $0.09

Eliem Therapeutics press release (NASDAQ:ELYM): Q2 GAAP EPS of -$0.56 misses by $0.09. Cash, cash equivalents and short- and long-term marketable securities was $134.7M as of June 30, 2022, as compared to $161.4M as of December 31, 2021. With the discontinuation of ETX-810, the company’s current cash, cash equivalents and short- and long-term marketable securities are now expected to fund operations into 2025.
Seeking Alpha • Aug 02

Eliem to discontinue development of lead asset as mid-stage pain trial fails

Clinical-stage biotech Eliem Therapeutics (NASDAQ:ELYM) announced on Tuesday that the company decided to discontinue further development of its lead asset ETX-810 after the failure of a mid-stage trial for the candidate in lumbosacral radicular pain (LSRP). The primary endpoint of the 148-patient Phase 2a trial was the change in the weekly average of the daily pain score from baseline to week 4, measured using the Pain Intensity Numerical Rating Scale (PI-NRS). The results indicated that ETX-810 did not indicate a statistically significant separation from the placebo in the primary endpoint, according to the company. The results were similar to previously disclosed data from another Phase 2 trial in diabetic peripheral neuropathic pain (DPNP) which also indicated a lack of separation for the treatment arm compared to the placebo, the company said.
Seeking Alpha • Jul 11

SVB Leerink cuts PT on Eliem Therapeutics, reaffirms Outperform rating

SVB Leerink on Monday cut its price target on Eliem Therapeutics (NASDAQ:ELYM) to $9 from $13. The new PT - based on an SOTP analysis that forecasts cash flows into early 2040s, with 11% discount rate - implies potential upside of 142.6% to ELYM's last close. The brokerage reiterated its Outperform rating, in-line with sell-side rating of Strong Buy. "Given the decreased bioavailability of ETX-155 observed in the phase 1b interim data readout in photosensitive epilepsy, we lowered our POS for all ETX-155 programs, which resulted in our PT moving to $9," analyst Marc Goodman wrote in a note to clients. "We still expect data from ETX-810 in lumbosacral radicular pain in Q3, although expectations are low after the failed phase 2 study in diabetic peripheral neuropathy," he added. ELYM stock, which fell as much as 5.4% on Monday, has declined 67.3% YTD.

Analys av ersättningar till VD

Hur har Aoife Brennan:s ersättning förändrats jämfört med Climb Bio:s resultat?
DatumTotal ersättningLönFöretagets resultat
Jun 30 2026n/an/a

-US$58m

Mar 31 2026n/an/a

-US$53m

Dec 31 2025US$3mUS$670k

-US$60m

Sep 30 2025n/an/a

-US$51m

Jun 30 2025n/an/a

-US$47m

Mar 31 2025n/an/a

-US$93m

Dec 31 2024US$6mUS$330k

-US$74m

Ersättning vs marknad: Aoife s total kompensation ($USD 2.92M ) är ungefär genomsnittet för företag av liknande storlek på US marknaden ($USD 3.54M ).

Ersättning vs inkomst: Ersättningen från Aoife har varit i linje med företagets resultat under det senaste året.

VD OCH KONCERNCHEF

Aoife Brennan (50 yo)

2.3yrs
Anställning
US$2,922,223
Kompensation

Dr. Aoife M. Brennan, M.D. M.B., Ch B., BAO, MMSc, MRCPI, is CEO, President at Climb Bio, Inc. (formerly known as Eliem Therapeutics, Inc.) and serves as its Director since June 2024 and served as its Inte...

Ledningsgrupp

NamnPositionAnställningKompensationÄgarskap
Aoife Brennan
CEO, President & Directorno dataUS$2.92m0.15%
$ 1.3m
Susan Altschuller
CFO & Principal Accounting Officerless than a yearUS$1.53minga uppgifter
Perrin Wilson
Chief Business Officer1.6yrsUS$1.59m0%
$ 0
Adam Villa
Senior Vice President of Technical Operationsless than a yearinga uppgifteringa uppgifter
Chandra Adams
Senior VP1.3yrsinga uppgifteringa uppgifter
Ashley Jones
Senior Vice President of People & Workforce Strategyless than a yearinga uppgifteringa uppgifter
Edgar Charles
Chief Medical Officer1.3yrsinga uppgifteringa uppgifter
1.1yrs
Genomsnittlig anställningstid
47yo
Genomsnittlig ålder

Erfaren ledning: CLYM s ledningsgrupp anses inte vara erfaren ( 1.1 års genomsnittlig anställningstid), vilket föreslår ett nytt team.

Styrelseledamöter

NamnPositionAnställningKompensationÄgarskap
Aoife Brennan
CEO, President & Director2.3yrsUS$2.92m0.15%
$ 1.3m
Douglas Williams
Independent Chairman of the Board1.8yrsUS$205.33k0%
$ 0
Kimberlee Drapkin
Independent Director1.5yrsUS$170.57k0%
$ 0
Alexander Cumbo
Independent Director1.5yrsUS$168.67k0%
$ 0
Stephen Thomas
Director2.3yrsUS$79.12k0.27%
$ 2.3m
Judith Dunn
Independent Director5.6yrsUS$89.75k0%
$ 0
Breanna O'Reilly
Directorless than a yearinga uppgifteringa uppgifter
1.8yrs
Genomsnittlig anställningstid
56.5yo
Genomsnittlig ålder

Erfaren styrelse: CLYM s styrelse anses inte vara erfaren ( 1.8 års genomsnittlig mandatperiod), vilket föreslår en ny styrelse.

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/09/11 21:01
Aktiekurs vid dagens slut2026/09/11 00:00
Intäkter2026/06/30
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Climb Bio, Inc. bevakas av 18 analytiker. 15 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Colleen KusyBaird
null nullBaird
Mayank MamtaniB. Riley Securities, Inc.